 Part 2: An interim analysis was conducted after accrual of 30 patients per arm and one experimental arm based upon a comparison of treatment-related toxicity was selected. The most toxic experimental arm was discontinued, and the trial continues comparing standard therapy arm I to the selected experimental regimen arm II as described in part 1. Please see the Arms section for more information regarding Part 2. 